To construct a recombinant fowl adenovirus 4(FAdV-4)expressing the Cap protein of goose astrovirus genotype 2(GoAstV-2),the expression cassette of Cap gene was inserted into the natural 1 966 bp deletion region of the FAdV-4 genome in the infectious clone p15A-cm-FAdV4-HNJZ.The resulted recombinant plasmid p15A-cm-FAdV4-HNJZ-Cap/GoAstV-2 was linearized with restriction enzyme and transfected into chicken hepatoma cell line(LMH)to rescue the recombinant FAdV-4 expressing the Cap protein of GoAstV-2,rF Ad V4-Cap/GoAstV-2.After 15 passages in LMH cells,the recombinant rFAdV4-Cap/GoAstV-2 was identified by PCR using primers flanking the insertion site of the Cap gene expression cassette and using viral genome DNA extracted from rFAdV4-Cap/GoAstV-2 infected LMH cells as template.LMH cells were in-fected with 15th passage rFAdV4-Cap/GoAstV-2 and indirect immunofluorescence was performed with a polyclonal antibody against Cap protein as the primary antibody.Western blot was carried out with lysates of rFAdV4-Cap/GoAstV-2 infected LMH cells.The in vitro replication dynamic of the 15th passage of the rFAdV4-Cap/GoAstV-2 was also investigated in LMH cells.The results demonstrated that the Cap gene of GoAstV-2 was presented in the genome of the recombinant vi-rus rF AdV4-Cap/Go Ast V-2,and could be expressed stably.The prepared recombinant virus in this study will lay a foundation for developing inactivated bivalent vaccine candidate against co-in-fection of FAdV-4 and GoAstV-2 in goose.

Deflazacort,as a glucocorticoid medication,is conductive to improving motor function and muscle strength,delaying the loss of ambulation,enhancing pulmonary function,reducing the risk of scoliosis,slowing the progression of cardiomyopathy,and increasing survival rates in patients with Duchenne muscular dystrophy(DMD).In February 2017,the U.S.Food and Drug Administration(FDA)approved deflazacort for the treatment of DMD.In May 2024,deflazacort entered Peking Union Medical College Hospital for desig-nated use through the ＂ temporary import＂ pathway.This article provides an overview of deflazacort from the perspectives of its mechanism of action,pharmacokinetics,clinical efficacy,and adverse effects,aiming to offer a reference for its rational and safe application in clinical practice.

OBJECTIVE:To conduct a Meta-analysis of evaluating the effects of whole-body vibration training on bone mineral density in postmenopausal women.METHODS:We searched CNKI,WanFang,PubMed,and Web of Science for studies on whole body vibration training to improve bone mineral density in postmenopausal women from database inception to April 3,2024,with the search terms whole-body vibration training,postmenopausal women,osteoporosis,and bone mineral density.Included indicators were lumbar spine(L1-L4,L2-L4),femoral neck,greater trochanter,Ward's triangle,and whole-body bone density.Revman 5.3 and R 4.3.3 were used for data analysis.RESULTS:(1)A total of 28 randomized controlled studies were included.(2)Vibration intensity:Vibration frequency＞20 Hz and amplitude＞2 mm could significantly increase the bone mineral density of the femoral neck,greater trochanter,Ward region,L1-L4 and L2-L4 lumbar vertebrae(P＜0.01,I2＞50％).(3)Training period and frequency:2-3 times per week,48-96 times per week,the bone mineral density at each site increased significantly(P＜0.05,I2＜50％).(4)Movement patterns:Dynamic training significantly increased bone mineral density in the femoral neck(P=0.03,/2=0％),greater trochanter(P＜0.001,I2=0％)and Ward region(P＜0.001,I2=0％);static squat significantly increased bone mineral density in L1-L4 lumbar spines(P＜0.001,I2=0％);and static multiple squatting was effective in improving bone mineral density in L2-L4 lumbar spines(P＜0.01,/2=0％)and the femoral neck(P=0.04,I2=34％).CONCLUSION:Whole-body vibration training has potential in improving bone mineral density in postmenopausal women.Recommended vibration frequencies and amplitudes are not less than 20 Hz and 2 mm,respectively,with no less than 48 training sessions.Static training is recommended for improving lumbar bone mineral density,while dynamic training is recommended for improving hip bone mineral density.

Deflazacort,as a glucocorticoid medication,is conductive to improving motor function and muscle strength,delaying the loss of ambulation,enhancing pulmonary function,reducing the risk of scoliosis,slowing the progression of cardiomyopathy,and increasing survival rates in patients with Duchenne muscular dystrophy(DMD).In February 2017,the U.S.Food and Drug Administration(FDA)approved deflazacort for the treatment of DMD.In May 2024,deflazacort entered Peking Union Medical College Hospital for desig-nated use through the ＂ temporary import＂ pathway.This article provides an overview of deflazacort from the perspectives of its mechanism of action,pharmacokinetics,clinical efficacy,and adverse effects,aiming to offer a reference for its rational and safe application in clinical practice.

To construct a recombinant fowl adenovirus 4(FAdV-4)expressing the Cap protein of goose astrovirus genotype 2(GoAstV-2),the expression cassette of Cap gene was inserted into the natural 1 966 bp deletion region of the FAdV-4 genome in the infectious clone p15A-cm-FAdV4-HNJZ.The resulted recombinant plasmid p15A-cm-FAdV4-HNJZ-Cap/GoAstV-2 was linearized with restriction enzyme and transfected into chicken hepatoma cell line(LMH)to rescue the recombinant FAdV-4 expressing the Cap protein of GoAstV-2,rF Ad V4-Cap/GoAstV-2.After 15 passages in LMH cells,the recombinant rFAdV4-Cap/GoAstV-2 was identified by PCR using primers flanking the insertion site of the Cap gene expression cassette and using viral genome DNA extracted from rFAdV4-Cap/GoAstV-2 infected LMH cells as template.LMH cells were in-fected with 15th passage rFAdV4-Cap/GoAstV-2 and indirect immunofluorescence was performed with a polyclonal antibody against Cap protein as the primary antibody.Western blot was carried out with lysates of rFAdV4-Cap/GoAstV-2 infected LMH cells.The in vitro replication dynamic of the 15th passage of the rFAdV4-Cap/GoAstV-2 was also investigated in LMH cells.The results demonstrated that the Cap gene of GoAstV-2 was presented in the genome of the recombinant vi-rus rF AdV4-Cap/Go Ast V-2,and could be expressed stably.The prepared recombinant virus in this study will lay a foundation for developing inactivated bivalent vaccine candidate against co-in-fection of FAdV-4 and GoAstV-2 in goose.

OBJECTIVE:To conduct a Meta-analysis of evaluating the effects of whole-body vibration training on bone mineral density in postmenopausal women.METHODS:We searched CNKI,WanFang,PubMed,and Web of Science for studies on whole body vibration training to improve bone mineral density in postmenopausal women from database inception to April 3,2024,with the search terms whole-body vibration training,postmenopausal women,osteoporosis,and bone mineral density.Included indicators were lumbar spine(L1-L4,L2-L4),femoral neck,greater trochanter,Ward's triangle,and whole-body bone density.Revman 5.3 and R 4.3.3 were used for data analysis.RESULTS:(1)A total of 28 randomized controlled studies were included.(2)Vibration intensity:Vibration frequency＞20 Hz and amplitude＞2 mm could significantly increase the bone mineral density of the femoral neck,greater trochanter,Ward region,L1-L4 and L2-L4 lumbar vertebrae(P＜0.01,I2＞50％).(3)Training period and frequency:2-3 times per week,48-96 times per week,the bone mineral density at each site increased significantly(P＜0.05,I2＜50％).(4)Movement patterns:Dynamic training significantly increased bone mineral density in the femoral neck(P=0.03,/2=0％),greater trochanter(P＜0.001,I2=0％)and Ward region(P＜0.001,I2=0％);static squat significantly increased bone mineral density in L1-L4 lumbar spines(P＜0.001,I2=0％);and static multiple squatting was effective in improving bone mineral density in L2-L4 lumbar spines(P＜0.01,/2=0％)and the femoral neck(P=0.04,I2=34％).CONCLUSION:Whole-body vibration training has potential in improving bone mineral density in postmenopausal women.Recommended vibration frequencies and amplitudes are not less than 20 Hz and 2 mm,respectively,with no less than 48 training sessions.Static training is recommended for improving lumbar bone mineral density,while dynamic training is recommended for improving hip bone mineral density.

Tuberculosis (TB) is one of the deadly diseases caused by Mycobacterium tuberculosis (Mtb), which presents a significant public health challenge. Treatment of TB relies on the combination of several anti-TB drugs to create shorter and safer regimens. Therefore, new anti-TB agents working by different mechanisms are urgently needed. FtsZ, a tubulin-like protein with GTPase activity, forms a dynamic Z-ring in cell division. Most of FtsZ inhibitors are designed to inhibit GTPase activity. In Mtb, the function of Z-ring is modulated by SepF, a FtsZ binding protein. The FtsZ/SepF interaction is essential for FtsZ bundling and localization at the site of division. Here, we established a yeast two-hybrid based screening system to identify inhibitors of FtsZ/SepF interaction in M. tuberculosis. Using this system, we found compound T0349 showing strong anti-Mtb activity but with low toxicity to other bacteria strains and mice. Moreover, we have demonstrated that T0349 binds specifically to SepF to block FtsZ/SepF interaction by GST pull-down, fluorescence polarization (FP), surface plasmon resonance (SPR) and CRISPRi knockdown assays. Furthermore, T0349 can inhibit bacterial cell division by inducing filamentation and abnormal septum. Our data demonstrated that FtsZ/SepF interaction is a promising anti-TB drug target for identifying agents with novel mechanisms.

Objective : To investigate the effect of platelet particles on the extent of intestinal inflammation and in⁃ testinal mucosal permeability in mice with dextran sodium sulfate induced colitis. Methods : The experiment was divided into four groups : normal control group ( n = 10 , drinking sterile distilled water + intraperitoneal injection of 0. 9% sodium chloride solution) , PMPs group ( n = 10 , drinking sterile distilled water + intraperitoneal injection of PMPs) , DSS model group ( n = 10 , drinking DSS solution + intraperitoneal injection of 0. 9% sodium chloride solution) , and experimental group ( n = 15 , drinking DSS solution + intraperitoneal injection of PMPs) . Peripheral blood⁃derived PMPs suspension was collected from inflammatory bowel disease ( IBD) patients. A colitis model was constructed in mice by allowing them to freely drink a 5% DSS solution for 1 week , followed by continuous intraperitoneal injection of PMPs for 7 days. Disease activity index (DAI) scores was recorded daily and the severity of intestinal inflammation with histopathological scores (HI) was assessed by HE staining of colon samples at the end of the experiment. Myeloperoxidase (MPO) , neutrophil elastase (NE) , citrullinated histone H3 (citH3) , and free DNA levels were measured in colon homogenate , observe intestinal mucosal structure by transmission electron microscopy , and intestinal permeability was tested using fluorescein isothiocyanate⁃dextran (FITC⁃D) . Results: Compared with the normal control group , the colonic mucosa of mice in the PMPs group showed edema , severe destruction of epithelial structure , extensive aggregation of inflammatory cells , and increased overall HI score (P < 0. 01) ; the levels of inflammatory factors such as IL⁃1β and TNF⁃α in colonic tissue homogenates of mice in the PMPs group increased (P < 0. 05) , and the expression of NETs increased (P < 0. 05) ; the plasma FITC⁃D level of mice in the PMPs group significantly increased (P < 0. 05) , and the permeability of intestinal mucosa increased. Compared with the DSS group , the experimental group mice had higher plasma FITC⁃D levels ( P < 0. 05 ) and more electron microscopic colonic epithelial damage. Conclusion PMPs induces NETs formation in mice , promotes colonic inflammation in mice , increases intestinal mucosal permeability and aggravates intestinal inflammation in mice with DSS colitis.

[This corrects the article DOI: 10.1016/j.apsb.2023.01.022.].